Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study

Table 2 Clinical characteristics, overall survival, and reverse transcription-quantitative polymerase chain reaction results of the n = 26 patients included in the final analysis

Patient number	Age	Gender	Site of primary cancer	Overall survival (mo)	Miss-match repair proteins expression	β-catenin expression (RT-qPCR) (relative expression with respect to reference gene average)	c-MYC expression (RT-qPCR) (relative expression with respect to reference gene average)	TGF-β expression (RT-qPCR) (relative expression with respect to reference gene average)	CMS
1	69	Male	Sigmoid	5	Proficient	0.185	2.864	0.201	CMS2
2	85	Female	Right colon	31	Proficient	0.100	0.352	0.169	CMS1
3	68	Female	Rectal and sigmoid	12	Proficient	0.042	0.384	0.076	CMS3
4	57	Male	Rectal and sigmoid	34	Proficient	2.684	18.817	9.778	CMS3
5	45	Female	Transverse	40	Proficient	1.812	19.445	5.231	CMS2
6	62	Male	Rectum	28	Proficient	0.010	4.401	0.973	CMS3
7	54	Male	Rectum	20	Proficient	0.301	3.234	1.433	CMS2
8	55	Male	Sigmoid	53	Proficient	0.080	1.870	11.718	CMS4
9	73	Male	Sigmoid	62	Proficient	0.038	0.645	0.461	CMS1
10	79	Male	Rectum	40	Proficient	0.121	2.080	3.513	CMS3
11	56	Female	Right colon	29	Proficient	0.235	3.799	14.700	CMS4
12	66	Female	Right colon	10	Proficient	0.351	6.004	76.116	CMS4
13	53	Male	Sigmoid	52	Proficient	0.233	3.863	2.688	CMS4
14	75	Male	Sigmoid	35	Proficient	0.089	0.760	0.205	CMS3
15	63	Male	Right colon	32	Proficient	0.089	0.760	0.466	CMS3
16	48	Female	Sigmoid	28	Proficient	0.038	1.110	0.498	CMS3
17	53	Female	Rectum	20	Proficient	0.084	1.124	0.801	Not classifiable
18	71	Female	Right colon	12	Proficient	0.083	1.540	0.897	CMS1
19	61	Female	Sigmoid	45	Proficient	0.106	9.208	6.820	CMS4
20	71	Male	Rectum	10	Proficient	0.013	0.855	0.065	CMS3
21	49	Female	Sigmoid	6	Deficient	0.063	2.968	1.871	CMS1
22	74	Male	Right colon	11	Deficient	0.047	0.552	0.249	CMS1
23	65	Female	Rectum	39	Proficient	0.059	0.828	0.084	Not classifiable
24	59	Female	Sigmoid	8	Proficient	0.045	1.324	0.152	CMS2
25	54	Male	Sigmoid	5	Deficient	0.036	0.543	0.127	CMS1
26	69	Male	Sigmoid	22	Proficient	0.192	5.025	2.654	CMS2

Each patient is individually identified in the first column on the left with a sequential number ranging from 1 to 26. Additionally, the consensus molecular subtype assigned based on the Tumour Board analysis is provided. RT-qPCR: reverse transcription-quantitative polymerase chain reaction; TGF-β: Transforming growth factor beta; CMS: consensus molecular subtype.